GlassScriptPhysician profile
Ahmed Radwan
NPI 1376575126
$9,256.35
in general payments reported to CMS, 2019-2025
37 companies · $1,943 in 2025
The $1,943 reported for 2025 was more than what 94% of Sports Medicine (Family Medicine) providers received nationally (typical 2025 total: $113).
See the full distribution for Sports Medicine (Family Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,748 · 2020: $1,758 · 2021: $1,396 · 2022: $666 · 2023: $523 · 2024: $1,223 · 2025: $1,943.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,656 · Education: $32.27.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,656.29 |
| Education | $32.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $2,175.05 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $1,131.96 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Allergan, INC. | $1,018.13 | 2019-2020 | |
| Abbvie INC. | $903.76 | 2021-2025 | |
| Lilly USA, LLC | $473.40 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Supernus Pharmaceuticals, INC. | $436.58 | 2019-2024 | Qelbree, Qelbree |
| Takeda Pharmaceuticals U.S.A., INC. | $306.02 | 2019-2025 | Trintellix |
| Lundbeck LLC | $305.94 | 2022-2025 | Rexulti, Vyepti |
| Pfizer INC. | $305.70 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $277.13 | 2019-2025 | Spravato |
| Boehringer Ingelheim Pharmaceuticals, INC. | $244.86 | 2021-2025 | Jardiance |
| Otsuka America Pharmaceutical, INC. | $234.52 | 2019-2025 | Abilify Maintena, Rexulti |
| Axsome Therapeutics, INC. | $207.81 | 2023-2025 | Auvelity, Symbravo, Sunosi |
| Amgen INC. | $200.75 | 2019-2025 | Otezla, Repatha |
| Merck Sharp & Dohme LLC | $176.76 | 2019-2020 |
Show all 37 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ahmed Radwan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.